Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance

BACKGROUND & AIMS: Induction of potent, HBV-specific immune responses is crucial to control and finally cure HBV. The therapeutic hepatitis B vaccine TherVacB combines protein priming with a Modified Vaccinia virus Ankara (MVA)-vector boost to break immune tolerance in chronic HBV infection. Par...

Descripción completa

Detalles Bibliográficos
Autores principales: Sacherl, Julia, Kosinska, Anna D., Kemter, Kristina, Kächele, Martin, Laumen, Sabine C., Kerth, Hélène A., Öz, Edanur Ates, Wolff, Lisa S., Su, Jinpeng, Essbauer, Sandra, Sutter, Gerd, Scholz, Martin, Singethan, Katrin, Altrichter, Jens, Protzer, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880034/
https://www.ncbi.nlm.nih.gov/pubmed/36714793
http://dx.doi.org/10.1016/j.jhepr.2022.100603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880034/
https://www.ncbi.nlm.nih.gov/pubmed/36714793
http://dx.doi.org/10.1016/j.jhepr.2022.100603

Ejemplares similares